SSI(SZ:002742) Sou Hu Cai Jing·2025-12-08 09:49Group 1 - The core point of the article is that *ST San Sheng (SZ 002742) announced a capital increase through the transfer of capital reserves, with stock suspension on December 9, 2025, and resumption on December 10, 2025 [1] - For the first half of 2025, *ST San Sheng's revenue composition is as follows: pharmaceuticals account for 59.77%, building materials account for 39.94%, and other businesses account for 0.29% [1] - As of the report date, *ST San Sheng has a market capitalization of 2.1 billion yuan [1] Group 2 - The article also highlights a report on the abuse of pregabalin leading to addiction in China, marking the first case of its kind, and points out vulnerabilities in online platforms allowing drug purchases without medical records [1]